Zoetis CEO Kristin Peck publicly stated on January 14, 2025, that the company's arthritis drug for dogs, Librela, is safe. This statement comes in response to recent concerns and an FDA warning regarding the medication.
Peck also highlighted the expanding market for animal care products, emphasizing Zoetis's commitment to its line of medications. The company aims to reassure stakeholders about the product's efficacy and safety profile.
This reaffirmation is crucial for maintaining trust with veterinarians and pet owners, especially following reports of side effects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.